United States

Dr. Valerie Fadok Joins Zoetis as Veterinary Specialist in Dermatology

New Leader Further Strengthens Team Managing Innovative Dermatology Portfolio


 FLORHAM PARK, NJ – Jan. 11, 2016 – Zoetis Inc. today announced the hiring of Valerie Fadok, DVM, Ph.D., Dip. ACVD, as Veterinary Specialist-Dermatology for the U.S. Western Region in the company’s Companion Animal Division.  Dr. Fadok will provide customer-focused education in small animal dermatology as well as technical support on dermatology-related products, services and initiatives. 

“I am thrilled to welcome a veterinarian of Dr. Fadok’s caliber to our Dermatology team,” stated Shelley L. Stanford, DVM, MS, MBA, Group Director, Companion Animal Division Veterinary Professional Services. “She is one of the most highly respected leaders in the veterinary community, and her experience as a key opinion leader will be invaluable to our customers and the patients they serve.” 

Dr. Fadok joins Dr. Candace Sousa, Dr. Michele Rosenbaum, and Dr. Andrew Hillier at Zoetis, rounding out a team of highly accomplished and respected international leaders in the field of small animal veterinary dermatology.  She also joins the company at a time when it is expanding its dermatology portfolio and offering differentiated new products to its customers. These products include the recently announced conditional license for Canine Atopic Dermatitis Immunotherapeutic*, a first-of-its-kind antibody therapy to help reduce clinical signs associated with atopic dermatitis in dogs, as well as APOQUEL® (oclacitinib tablet)and CONVENIA® (cefovecin sodium). 

"I am very excited to have the opportunity to join Zoetis. I have enjoyed using Zoetis products over the decades for their efficacy and safety in the dermatologic patients I have treated.  It is also clear that Zoetis is focused on education and helping veterinarians succeed, particularly with chronic inflammatory skin diseases such as atopic dermatitis and its associated pyodermas,” said Dr. Fadok. “Additionally, the new monoclonal antibody therapy has allowed me to give rapid comfort to some itchy atopic dogs, and it is thrilling to have this technology in veterinary medicine at last.  I look forward to what the future holds."

Dr. Fadok obtained her Doctorate of Veterinary Medicine from Washington State University in 1978.  She completed a small animal and exotics internship at the West Los Angeles Veterinary Medicine Group, a residency in Veterinary Dermatology at the University of Florida,  and achieved diplomate status from the American College of Veterinary Dermatology.  She obtained a Ph.D. in pathology with a focus on immunology from the University of Health Sciences Center (Denver, CO) and completed her post-doctorate fellowship at the National Jewish Medical and Research Center.  

Dr. Fadok’s extensive teaching experience includes positions as  Associate Professor of Dermatology  at the College of Veterinary Medicine, University of Tennessee; the College of Veterinary Medicine, University of Florida; and the College of Veterinary Medicine, Texas A&M University. She also served as Associate Faculty Member and Associate Professor, Department of Pediatrics at the National Jewish Medical and Research Center. Her clinical work includes positions at several large, influential specialty referral practices in Colorado and Texas.  Dr. Fadok has edited, reviewed and written many chapters on dermatology topics for prominent veterinary textbooks and journals, and conducted and published significant medical research within peer-reviewed veterinary journals. Additionally, she has given hundreds of Veterinary Dermatology and Immunology presentations at local, national and international veterinary conferences.

About Zoetis
Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2014, the company generated annual revenue of $4.8 billion. With approximately 10,000 employees worldwide at the beginning of 2015, Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in 120 countries. For more information, visit www.zoetis.com.
 
IMPORTANT SAFETY INFORMATION: Do not use APOQUEL in dogs less than 12 months of age or those with serious infections. APOQUEL may increase the chances of developing serious infections, and may cause existing parasitic skin infections or pre-existing cancers to get worse. APOQUEL has not been tested in dogs receiving some medications including some commonly used to treat skin conditions such as corticosteroids and cyclosporines. Do not use in breeding, pregnant, or lactating dogs. Most common side effects are vomiting and diarrhea. APOQUEL has been used safely with many common medications including parasiticides, antibiotics and vaccines. For more information, please see the full Prescribing Information.

IMPORTANT SAFETY INFORMATION: People with known hypersensitivity to penicillin or cephalosporins should avoid exposure to CONVENIA. Do not use in dogs or cats with a history of allergic reactions to penicillins or cephalosporins. Side effects for both dogs and cats include vomiting, diarrhea, decreased appetite/anorexia and lethargy. See full Prescribing Information.

For Further Information,Contact:

Colleen T. White
973-822-7203
colleen.white@zoetis.com

* This product license is conditional. Efficacy and potency test studies are in progress.